Navigation Links
International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery

SINGAPORE, Sept. 27 /Xinhua-PRNewswire/ -- NeuroAid(TM) is the first natural compound to be studied in a large clinical trial focused on stroke recovery starting in the acute stage.

The CHIMES study is a multi-center double-blind placebo-controlled randomized trial to evaluate the efficacy of NeuroAid(TM) in reducing neurological deficit and improving independence in patients in rehabilitation, with treatment starting within 48 hours of a stroke. Already studied in a rehabilitation setting with initiation of treatment within 14 days of stroke incidence, NeuroAid(TM) will now be evaluated when administered in the acute stage, with periodic assessments for three months. The study will begin enrollment of 1,100 patients in early October 2007 at several hospitals in Singapore, followed by hospitals in the Philippines and in Thailand.

The study will be conducted by CHIMES Society, an international partnership of Key Opinion Leaders in stroke whose objective is to establish new stroke treatments.

Professor Marie-Germaine Bousser, Head of the Neurology Department at Lariboisiere Hospital in Paris, France and member of the Council of the American Stroke Association, commented, ''Recent drug trials in the acute treatment of stroke have unfortunately all been negative. It is thus very exciting to take a completely new approach and to scientifically test in different populations a compound that has long been used in Traditional Chinese Medicine.''

David Picard, CEO of Moleac, the Singapore/Biopolis-based global biopharmaceutical company that develops and markets NeuroAid(TM) outside of China, said: ''We are delighted at the interest NeuroAid(TM) has generated in the medical community worldwide. Over 200,000 patients in China alone are using NeuroAid(TM) every year, and patient feedback from other countries is very positive. Our next milestone is to generate clinical data in the acute phase, with studies that meet the standards of European and U.S. regulatory authorities. ''Our ultimate goal is to see NeuroAid(TM) included in key treatment guidelines for stroke victims, making its benefits available to all patients who need it,'' David added.

NeuroAid(TM)'s efficacy and safety was tested in a multi-centre double blind randomized clinical trial conducted on 605 patients in China in 1999- 2000. Patients taking NeuroAid(TM) were shown to be 2.11 times more likely to reach functional independence and 1.7 times more likely to reduce their neurological deficit by at least 55% than patients who did not take the product. It helped improve stroke patients' ability to recover even when treatment was started several weeks after the onset of stroke.

About NeuroAid(TM)

NeuroAid(TM) is a Traditional Chinese Medicine that provides faster and more extensive recovery of motor and cognitive functions in stroke patients during rehabilitation. It is a combination of fourteen all-natural ingredients from the Chinese medicinal pharmacopoeia, formulated according to international Good Manufacturing Practice (GMP) standards. It is marketed internationally by Moleac, the biopharmaceutical company that identified the product in China as the first medicine to help improve stroke recovery. NeuroAid(TM) is currently marketed in Singapore as a Chinese proprietary medicine, and in other countries in the region as a dietary supplement. It is also sold internationally by Moleac via the website . With the CHIMES study, NeuroAid(TM) is the first traditional medicine in the world to be studied in a large scale evidence-based clinical trial.

About Moleac

Moleac is a biopharmaceutical company based in Biopolis, a world-class purpose built complex for biomedical sciences research in Singapore ( ). Moleac identifies promising medicines discovered in China and develops them into Western mainstream medicine. Moleac also develops innovative technologies and medical products in-licensed from Europe and the US, and markets them in Asia. Focusing on patients' greatest needs and specific unmet medical needs, Moleac drives research, development and registration for a pipeline of drugs and devices in various stages of development. Moleac seeks partners to bring these products to market and will continue to evaluate new opportunities.

Moleac's first product derived from Traditional Chinese Medicine, NeuroAid(TM), has gained market approval in two countries in 2006 and will be available to stroke sufferers around the world in 2007-2008. Moleac also plans the launch of a smoking cessation therapy that will reach key global markets in 2007.

About CHIMES Society

CHIMES Society is an international partnership of Key Opinion Leaders in stroke whose objective is to establish new stroke treatments. Members include physicians, academics, and clinicians, several of which are renowned neurologists from Europe and Asia. The team received a grant from the National Medical Research Council (NMRC) of Singapore to undertake the study over a period of two years. For further information visit .

DISCLOSURE NOTICE: The information contained in this release is as of September 24, 2007. Moleac assumes no obligation to update any forward- looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about the potential benefits of NeuroAid(TM) that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; and competitive developments.



Kristy Weller

Tel: +65-6534-7250

Mobile: +65-9069-3844


Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/22/2017)... SAN DIEGO , Sept. 22, 2017 ... ll medical device is now successfully helping those with ... Union. Fibromyalgia diagnosed Amanda in ... getting dressed and washing my hair, experiencing no sleep ... body in painful spasm… I cannot recommend [the AVACEN ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International Association of ... of excellence for the field of eating disorders, announces the opening of early ... in Orlando, Florida at the Omni Resort at ChampionsGate. , The ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... viewers the lowdown on sciatica in a new episode of "Success Files," which ... current events and innovation and investigates each subject in-depth with passion and integrity. ...
(Date:10/12/2017)... CA (PRWEB) , ... October 12, 2017 , ... ... Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent technology. ... a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
Breaking Medicine News(10 mins):